Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note. 2003

Jun Shinoda, and Hirohito Yano, and Shin-Ichi Yoshimura, and Ayumi Okumura, and Yasuhiko Kaku, and Toru Iwama, and Noboru Sakai
Department of Neurosurgery, Gifu University School of Medicine, Gifu, Japan. junshino@cc.gifu-u.ac.jp

The authors have recently performed a fluorescence-guided tumor resection procedure by using high-dose fluorescein sodium without any special surgical microscopes for the intraoperative visualization of glioblastoma multiforme (GBM), and they report on the actual procedure and clinicopathological findings. Thirty-two patients with GBMs underwent tumor resection during which this fluorescence-guided procedure was used. Fluorescein sodium (20 mg/kg) was intravenously injected after dural opening at the craniotomy site. The tumor was stained almost homogeneously yellow and the color was intense enough to be readily perceived for resection. The center of the solid lesion was stained a deep yellow and surrounded by a transition zone that was faintly stained. The colored lesion was clearly distinguishable from the unstained zone outside the GBM, particularly in the white matter. Both the deeply and faintly stained regions included endothelial proliferation and dense tumor cells. In the unstained region, less dense tumor cells were consistently revealed; however, no endothelial proliferation could be seen. Gross-total resection (GTR) was successful in 84.4% of the patients who received an injection of fluorescein sodium, which accounted for 100% of those in whom all the visible yellow color (both the deeply and faintly stained regions) was judged to have been resected during operation. Gross-total resection was performed in 100% of the patients who underwent the fluorescence-guided procedure and assigned to Stage I, a GBM stage in which, as a therapeutic policy, the tumor should be resected as radically as possible. The GTR rates in patients who received fluorescein sodium were significantly higher than those in patients who did not (73 patients with GBMs who underwent tumor resection without the fluorescence-guided procedure). Although the extent of surgery was revealed to be one of the significant and independent prognostic factors for GBM, the fluorescein sodium-guided resection procedure was not a significant or independent prognostic factor in this series. This surgical procedure does not require any special surgical microscopic equipment and is simple, safe, useful, readily accomplished, and universally available for resection of GBMs. Its efficacy simplifies the surgical procedure of navigating the stained lesion from the unstained area to achieve GTR of GBMs, which can be demonstrated on magnetic resonance images.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D005260 Female Females
D005456 Fluorescent Dyes Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. Flourescent Agent,Fluorescent Dye,Fluorescent Probe,Fluorescent Probes,Fluorochrome,Fluorochromes,Fluorogenic Substrates,Fluorescence Agents,Fluorescent Agents,Fluorogenic Substrate,Agents, Fluorescence,Agents, Fluorescent,Dyes, Fluorescent,Probes, Fluorescent,Substrates, Fluorogenic
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Jun Shinoda, and Hirohito Yano, and Shin-Ichi Yoshimura, and Ayumi Okumura, and Yasuhiko Kaku, and Toru Iwama, and Noboru Sakai
December 2012, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Jun Shinoda, and Hirohito Yano, and Shin-Ichi Yoshimura, and Ayumi Okumura, and Yasuhiko Kaku, and Toru Iwama, and Noboru Sakai
August 2018, Zhonghua wai ke za zhi [Chinese journal of surgery],
Jun Shinoda, and Hirohito Yano, and Shin-Ichi Yoshimura, and Ayumi Okumura, and Yasuhiko Kaku, and Toru Iwama, and Noboru Sakai
February 2008, British journal of neurosurgery,
Jun Shinoda, and Hirohito Yano, and Shin-Ichi Yoshimura, and Ayumi Okumura, and Yasuhiko Kaku, and Toru Iwama, and Noboru Sakai
February 2018, Journal of neurosurgery,
Jun Shinoda, and Hirohito Yano, and Shin-Ichi Yoshimura, and Ayumi Okumura, and Yasuhiko Kaku, and Toru Iwama, and Noboru Sakai
August 2021, Journal of clinical medicine,
Jun Shinoda, and Hirohito Yano, and Shin-Ichi Yoshimura, and Ayumi Okumura, and Yasuhiko Kaku, and Toru Iwama, and Noboru Sakai
December 2007, Minimally invasive neurosurgery : MIN,
Jun Shinoda, and Hirohito Yano, and Shin-Ichi Yoshimura, and Ayumi Okumura, and Yasuhiko Kaku, and Toru Iwama, and Noboru Sakai
December 2018, Clinical neurology and neurosurgery,
Jun Shinoda, and Hirohito Yano, and Shin-Ichi Yoshimura, and Ayumi Okumura, and Yasuhiko Kaku, and Toru Iwama, and Noboru Sakai
June 2019, Biomaterials,
Jun Shinoda, and Hirohito Yano, and Shin-Ichi Yoshimura, and Ayumi Okumura, and Yasuhiko Kaku, and Toru Iwama, and Noboru Sakai
January 2010, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Jun Shinoda, and Hirohito Yano, and Shin-Ichi Yoshimura, and Ayumi Okumura, and Yasuhiko Kaku, and Toru Iwama, and Noboru Sakai
May 2019, World neurosurgery,
Copied contents to your clipboard!